ETF Investing

Showing 524 articles
Business

Grid Dynamics' Paradox: Soaring Earnings Fail to Halt Stock Slide

Despite a staggering 425% surge in earnings per share over the past year, shareholders of Grid Dynamics Holdings (NASDAQ: GDYN) have watched the stock price plummet 64%. This disconnect between robust financial performance and market valuation highlights the complex forces driving investor sentiment beyond the fundamentals.

Business

Oxford Lane Capital Cuts Payout Amid Market Turbulence, NAV Takes a Hit

Oxford Lane Capital (OXLC) reported a challenging third fiscal quarter, marked by a significant drop in net asset value and investment income, prompting management to reduce its monthly distribution. The firm cited volatile conditions in the CLO and leveraged loan markets as key headwinds, while outlining a strategy to preserve capital for opportunistic investments.

Business

Quarterhill's Five-Year Plunge: A 66% Loss Tests Investor Patience

Quarterhill Inc. (TSE:QTRH) shareholders have endured a punishing five-year period, with the stock's value plummeting nearly 70%. Despite modest revenue growth, the market's verdict has been harsh, raising questions about the company's path to profitability and the perils of long-term bets in turbulent sectors.

Business

Workday's Steep Slide: A Value Bet or Value Trap for Investors?

As the S&P 500 notches another year of robust gains, the concentrated nature of the rally has left some high-flying tech names like Workday in the dust. Hotchkis & Wiley's latest investor letter reveals the HR software giant was a significant drag on its value fund in Q4 2025, with shares down over 33% in a year. Against a backdrop of stretched market valuations, we examine whether this sell-off presents a compelling entry point or signals deeper troubles.

Business

Carnival Stock: A Deep Value Play After Debt Pivot and Travel Rebound?

Carnival Corporation's shares have surged over three years, yet a detailed financial analysis suggests the cruise giant may still be trading at a significant discount. As the industry navigates post-pandemic recovery and debt reduction, investors are weighing if the current price reflects underlying value or lingering risks.

Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.